Oramed Pharmaceuticals 8/14/2025 Earnings Report

Oramed Pharmaceuticals EPS Results

• Actual EPS: -$0.05
• Consensus EPS: -$0.04
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: N/A

Oramed Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Oramed Pharmaceuticals Announcement Details

• Date: 8/14/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Oramed Pharmaceuticals (NASDAQ:ORMP) is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials. ORMD-0801 aims to improve glycemic control by mimicking natural pancreatic insulin release while offering convenience and increased compliance compared to subcutaneous injections. In parallel, Oramed is developing ORMD-0901, an oral version of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist used in diabetes and obesity management. Oramed has also initiated preclinical work on an oral COVID-19 vaccine, ORMD-0162, underscoring the versatility of its delivery platform.

Since its founding in 2006 by Miriam Kidron and Nadav Kidron, Oramed has established collaborations and licensing arrangements across multiple regions. The company has entered strategic partnerships for commercialization rights in key markets, including China and Europe, in an effort to accelerate global access to its oral therapies. Oramed’s clinical programs are conducted in compliance with international regulatory standards, with trial sites in North America, Europe and Israel.

Led by Chief Executive Officer Nadav Kidron, Oramed’s management team combines expertise in pharmaceutical research, clinical development and regulatory affairs. The company’s board and scientific advisory committees include veterans of the biotech and diabetes care industries, guiding the advancement of its pipeline. Oramed is publicly traded on the Nasdaq Stock Market under the ticker symbol “ORMP,” reflecting its commitment to transparency and corporate governance as it seeks to revolutionize the treatment of chronic diseases.